Rapamycin and Alzheimer's disease: Time for a clinical trial?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30674654.
- Also identified by DOI 10.1126/scitranslmed.aar4289 and PMC identifier 6762017.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.
Medical subject headings
- Alzheimer Disease
- Clinical Trials as Topic
- Sirolimus